About this Research Topic
that is causative agent of CML.
As new STKIs have been developed, their spectrum of action has been increasingly less specific to BCR-ABL1, affecting other unrelated tyrosine kinases. This Research Topic will be the first to update the current situation of STKIs for treating CML and how they are progressively being used for treating other cancer types.
Second, as new side effects different from the expected ones may be detected as drugs are increasingly used in the clinic, we will update the most important side effects that have been recently detected, which is especially important for ponatinib.
Third, some STKIs show immunomodulatory properties that have not been fully understood yet and therefore, we will focus on this immunomodulatory activity, as well as on the increasing interest in the role of STKIs in inflammation and senescence.
Last but not least, another intriguing property of STKIs is their antiviral effect, likely by enhancing cytotoxic pathways that may be shared by antitumor and antiviral responses. Therefore, we will analyze the remarkable ability of some STKIs to enhance both humoral and cellular response against cytomegalovirus and even the possibility of using STKIs against HIV-1 infection will be explored.
Keywords: Src tyrosine kinase inhibitors, chronic myeloid leukemia, immunomodulatory properties, antiviral effect, inflammation and senescence
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.